Ocugenix is developing therapies for angio-fibrotic diseases of the eye such as wet macular degeneration and diabetic retinopathy. These diseases are caused by an aberrant wound response in the back of the eye. Ocugenix’s compound triggers the process of wound resolution to cause the regression of the excessive fibrosis and vasculature recruited to heal the wound. The ability to cause regression of the pathological vessels and fibrosis in AMD and DR offers the patient the best hope of restoring lost sight.
https://ocugenix.com/